- Conditions
- Total Parenteral Nutrition-induced Cholestasis, Cholestasis, Short Bowel Syndrome, Gastroschisis, Intestinal Atresia, Infant, Premature, Diseases, Cholestasis of Parenteral Nutrition
- Interventions
- Omegaven
- Drug
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 38
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Intralipid 20%, Glucose infusion
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Abscess
- Interventions
- Methylene Blue, Lipid Emulsion, Insertion of optical fiber, Laser Illumination (pre-defined dose), Optical Spectroscopy Measurement, Laser Illumination (patient-specific dose), Standard of care abscess drainage
- Drug · Device · Procedure
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 2
- States / cities
- Rochester, New York
- Conditions
- Obesity, Infertility, Hypogonadotropic Hypogonadotropism, Hyperinsulinemia
- Interventions
- Insulin, Intralipid, Dextrose, Heparin, GnRH, Hyperinsulinemic Euglycemic Clamp
- Drug · Procedure
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 38 Years · Female only
- Enrollment
- 84 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2026
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- HIV Infections
- Interventions
- Fat Emulsion 2%, Fat Emulsion 20%
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years to 60 Years
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 2
- States / cities
- Miami, Florida • East Orange, New Jersey
- Conditions
- Advanced Malignant Neoplasm
- Interventions
- Fat Emulsion, Placebo
- Dietary Supplement · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- General Anesthesia
- Interventions
- HSK3486, propofol, Placebo
- Drug
- Lead sponsor
- Haisco-USA Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Total Parenteral Nutrition-induced Cholestasis
- Interventions
- Omegaven, Omegaven
- Dietary Supplement · Drug
- Lead sponsor
- Pediatrix
- Other
- Eligibility
- 14 Days to 2 Years
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Dyspnea, Hypertension, Acute Heart Failure
- Interventions
- Stage 1: Clevidipine (double-blinded), Stage 1: Placebo (double-blinded), Stage 2: Clevidipine (open-label), Stage 2: Standard of Care (open-label)
- Drug
- Lead sponsor
- The Medicines Company
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 9
- States / cities
- Montgomery, Alabama • Tucson, Arizona • St Louis, Missouri + 5 more
- Conditions
- Cholestasis, Cholestasis of Parenteral Nutrition
- Interventions
- Omegaven
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 14 Days to 5 Years
- Enrollment
- 293 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2020
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Blood Pressure, Hypertension
- Interventions
- Dextrose 20 % in 500 ML Injection, Intralipid, Saline, Ascorbic acid
- Drug
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Obesity
- Interventions
- Galantamine, Placebo Oral Capsule, Intralipid, Heparin
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 60 Years · Female only
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Liver Injury
- Interventions
- Omegaven™, Historical Controls
- Drug · Other
- Lead sponsor
- Children's Hospital Los Angeles
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2019
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Hypertension, Diabetes
- Interventions
- Salsalate, Carvedilol, Placebo, Intralipid 20%
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Cardiovascular Diseases, Hyperlipidemias
- Interventions
- Lipid Challenge, Glucose Challenge, Mixed Meal Challenge
- Dietary Supplement
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- PreDiabetes
- Interventions
- Intralipid and heparin, Saline
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- HIV Infections
- Interventions
- Fat Emulsion 2%, Fat Emulsion 20%
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years to 60 Years
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- East Orange, New Jersey
- Conditions
- Breast Abscess
- Interventions
- Standard of care breast abscess drainage, Methylene Blue, Lipid Emulsion, Insertion of optical fiber, Laser illumination, Photodynamic therapy
- Procedure · Drug · Device
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2032
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Healthy, Type 2 Diabetes
- Interventions
- Saline, Exendin-9,39, Saline + Intralipid/Heparin, Exendin-9,39 + Intralipid/Heparin
- Biological
- Lead sponsor
- Adrian Vella
- Other
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Ovarian Failure, Perimenopausal Disorder, Hormone Disturbance
- Interventions
- lipoaspiration harvest tSVF, Platelet Rich Plasma, Endovaginal Ultrasound, Cellular Isolation cSVF, Normal Saline (NS) .9% 10 mL Injection, emulsification tSVF
- Procedure · Device · Drug
- Lead sponsor
- Black Tie Medical, Inc.
- Industry
- Eligibility
- 35 Years to 60 Years · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Colchester, Vermont
- Conditions
- Cholestasis, Liver Disease
- Interventions
- Omegaven IV
- Drug
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 1 Day to 5 Years
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Staten Island, New York
- Conditions
- Insulin Resistance
- Interventions
- Intralipid, Saline
- Drug
- Lead sponsor
- Pennington Biomedical Research Center
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Baton Rouge, Louisiana
- Conditions
- Healthy
- Interventions
- Somatostatin, Dextrose, Insulin, Intralipid
- Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 25 Years to 65 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Type 2 Diabetes, Hypertension
- Interventions
- Rosiglitazone, Normal saline 0.9%, Intralipid 20%
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia